39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY
Breier A, Dickerson F, Buchanan R, Marder S, Neuchterlein K, D’Souza D, Francis M, Radnovich A, Yolken R, Preskorn S, Macaluso M, Yang Z, Mehdyoun N, Kakar R, Dunn W, Hoffmeyer D, Maguire G. 39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY. Schizophrenia Bulletin 2018, 44: s63-s63. PMCID: PMC5888721, DOI: 10.1093/schbul/sby014.162.Peer-Reviewed Original ResearchEarly phase schizophreniaHSV-1 seropositiveHSV-1Cognitive impairmentNegative subjectsHerpes virusPrevious small clinical trialsDuration of psychosisEfficacy of valacyclovirDouble-blind trialSmall clinical trialsHerpes virus infectionHerpes simplex virus type 1Treatment of schizophreniaSimplex virus type 1Life-long infectionVirus type 1Treatment outcome analysisMemory scoresFull therapeutic potentialPlacebo groupAdjunctive placeboInflammatory markersPrimary outcomeHuman CNS